Loading...
•
Sep 30, 2022
Amneal Q3 2022 Earnings Report
Amneal's third quarter results reflect solid performance across its diversified portfolio, driven by new product innovation, leveraging key capabilities, and strong execution.
Key Takeaways
Amneal Pharmaceuticals reported its Q3 2022 financial results with net revenue of $546 million, a GAAP net loss of $3 million, and an adjusted EBITDA of $126 million. The company is maintaining its full year 2022 outlook.
Net revenue in Q3 2022 was $546 million, a 3.2% increase compared to Q3 2021.
GAAP Net loss attributable to Amneal Pharmaceuticals, Inc. was $3 million in Q3 2022 compared to a net loss of $4 million in Q3 2021.
Adjusted EBITDA in Q3 2022 was $126 million, a decrease of 5.1% compared to Q3 2021, reflective of investments to drive upcoming new product launches.
Diluted loss per share and adjusted diluted EPS in Q3 2022 were $(0.02) and $0.14, respectively, compared to $(0.03) and $0.21, respectively, in Q3 2021.
Amneal
Amneal
Amneal Revenue by Segment
Revenue by Segment
Affordable Medicines Revenue
CapyFin.comSpecialty Revenue
CapyFin.comAvKARE Revenue
CapyFin.com Forward Guidance
The Company is maintaining its previously provided full year 2022 guidance.
Positive Outlook
- Net revenue $2.15 billion - $2.25 billion
- Adjusted EBITDA $500 million - $520 million
- Adjusted diluted EPS $0.65 - $0.70
- Operating cash flow $200 million - $225 million
- Capital expenditures $65 million - $75 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income